Applied Data Research Finds Regional Factors and Importance of Supplemental Indications Increase the Value of Alliances
(Nashua, NH) – Previously considered an ‘untreatable’ disease segment, the last decade has seen advances in therapeutic drugs that have opened up the field of autoimmune diseases to a growing number of new treatment options. Numerous pipeline candidates targeting a range of cytokines and chemokines that comprise the immune system cascade are now winding their way through the clinical development process. For autoimmune sector participants, successfully navigating this therapeutic landscape is presenting new challenges.
Perhaps more than any other disease segment, autoimmune conditions and the companies that market treatment for then are benefiting from the potential for expanded indications. A typical strategy for many drug candidates is to initially target a larger, well-defined segment such as Rheumatoid Arthritis and then pursue secondary indications – for example – Lupus or Psoriasis, once the brand has been launched and established. Such a strategy requires resources and risks that can strain all but the largest players, making alliances highly attractive.
Because of the individual genetic variability underlying the incidence and severity of autoimmune symptoms, regional variations in the market for autoimmune therapeutics can be significant. This variability is compounded by differences in treatment protocols and cultural factors, which combine to make alliance partnerships with regional players of increased importance.
The dynamics of therapeutic intellectual property is another factor fostering alliance activity in the autoimmune sector. Because antibody technology forms the basis for much of the current generation of autoimmune disease treatment technology, mid-to-large pharma companies are increasingly in-licensing therapeutic candidates from smaller specialty laboratories, often at the pre-clinical stage.
More information is also available at
http://www.applieddata.org/Autoimmune_Disease.htm
About Applied Data
Applied Data Research is a healthcare therapeutics consulting firm focused on medical market strategies, product commercialization, venture development, and market research. We assist medical market participants in achieving their business objectives through the creation of detailed business development strategies, product commercialization programs, and comprehensive market and technology research and analysis.
Contact:
Greg Stone
Voice: 603-595-6225
Fax: 603-804-0466
www.applieddata.org
Source: Applied Data Research
Comment and add to the story without registration, but keep the comments meaningful please. Links are not accepted.
